Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights

A new topical treatment called RT1640 claims to reverse AGA using cyclosporine A, Minoxidil, and a new chemical entity, RT175. Users are skeptical due to lack of clinical trial data and inconsistent before-and-after photos.

Novo is exploring hair loss treatments, possibly linked to GLP-1 drugs like Ozempic, which may contribute to hair loss. Some users are skeptical about new treatments, suggesting existing drugs like finasteride and minoxidil are being rebranded.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

The conversation discusses the use of pyrilutamide as an adjunct treatment for hair loss, particularly for those already using finasteride and minoxidil. Users share mixed experiences, with some reporting side effects like numbness and gynecomastia, while others note its potential benefits in reducing shedding and scalp itchiness.

Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.